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ABSTRACT
 
Objectives: 
 
To assess the cost-effectiveness of bicaluta-
mide (Casodex
 
TM
 
) as adjuvant treatment in early prostate
cancer (EPC).
 
Methods: 
 
A Markov state transition model was devel-
oped, using disease progression rates from a large
(N = 8113) clinical trial program comparing bicalutamide
in addition to standard care with standard care alone.
Utility scores for different disease stages were obtained
from published reports. Costs of disease progression were
obtained from a retrospective patient chart analysis in six
Belgian centers (n = 60). The time horizon was 15 years
and the analysis was conducted from the public payer per-
spective.
Results: The model showed good validity in predicting
clinical outcomes. At a time horizon of 15 years, an incre-
mental cost-effectiveness of 27,059€/QALY was obtained.
The main factors inﬂuencing conclusions included the
time horizon, the duration of bicalutamide treatment,
which was set at a maximum (5 years) in the base case,
and possible differences in prognosis of metastatic cancer
between comparators. Also the discounting of health
effects signiﬁcantly altered cost-effectiveness ratios. Many
of these inﬂuences are inherently associated with any cost-
effectiveness analysis related to treatment of early, slowly
progressing malignancies because such an analysis
requires a sufﬁcient time horizon to include not only the
treatment costs but its beneﬁts as well.
Conclusion: Based on the current data, bicalutamide
appears to be a cost-effective option for adjuvant treat-
ment of EPC.
Keywords: adjuvant, bicalutamide, cost-effectiveness,
early prostatic neoplasm.
 
Introduction
 
Prostate cancer is the most common cancer in men
in Western countries. It is rarely diagnosed until
men are more than 50 years of age, after which the
likelihood of diagnosis increases rapidly between
the ages of 60 and 80 years [1]. Localized disease is
deﬁned as organ-conﬁned cancer, with no lymph
node or distant metastases. The cancer becomes
locally advanced when it spreads to nearby struc-
tures or regional lymph nodes. Both localized and
locally advanced diseases are included in the term
“early prostate cancer” (EPC). Advanced disease is
characterized by the development of distant metas-
tases. Finally as the disease progresses further, it
becomes independent of hormones for stimulation
of growth, and is called hormone-refractory. With
increasing diagnostic efforts and improving tech-
niques, early stage diagnosis is increasing. Because
rates of retreatment after standard EPC treatment
with curative intent have been reported to reach
approximately 16% to 20% within 2 years, and up
to 35% within 5 years [2], further therapeutic
options for EPC are being explored. The use of
bicalutamide (Casodex
 
TM
 
) as adjuvant treatment in
EPC is being evaluated in a very large prostate can-
cer clinical trial program (
 
N
 
 
 
=
 
 8113) [3]. At a
median follow-up of 3 years, bicalutamide was
shown to signiﬁcantly reduce the risk of objective
disease progression. Because cost-effectiveness
(value for money) is becoming an increasingly
important criterion to assess new medical technol-
ogies that are submitted for reimbursement, the
objective of this project was to assess the cost-
effectiveness  of  bicalutamide  as  adjuvant  therapy
in EPC.
 
Methods
 
We performed a cost-effectiveness analysis of bical-
utamide for adjuvant treatment in EPC expressed as
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cost per quality adjusted life year (QALY), taking
the Belgian health-care payers (RIZIV/INAMI) per-
spective. Because up to 50% of long-term (over 10–
15 years) prostate cancer survivors eventually die as
a direct consequence of prostate cancer [4] (Aus
1994 in [5]), patients need to be followed for at
least 15 years to assess the survival beneﬁt from a
therapeutic intervention [5]. Because a lifetime pre-
diction (i.e., beyond 15 years) is subject to more
uncertainty about future treatment options, a time
horizon of 15 years was deemed justiﬁed for this
analysis. It is, however, important to evaluate the
impact of the time horizon on results. Therefore, the
time horizon was subject to sensitivity analysis
(Table 1). Future costs and effects were discounted
at 3% [6].
 
Model
 
A Markov state transition model [7,8] was devel-
oped using DATA Pro software (Version 4.0, Tree-
Age Software Inc., Williamstown, MA, United
States, 2003), consisting of mutually exclusive
health states and 15 ﬁxed time periods of 1 year.
The model describes the natural history of EPC and
its management from diagnosis comparing a sce-
nario “bicalutamide in addition to standard care”
with a scenario “standard care only.” A simpliﬁed
structure of the model is shown in Figure 1. The
model starts at the time of EPC diagnosis. After
EPC (initial health state), patients can evolve to
either “follow-up after early prostate cancer,” that
is, as long as they do not relapse from “biochemical
progression” (deﬁned as PSA doubling), “metasta-
sis” (metastasis based on objective proof or clinical
symptoms), or “death.” From the state “biochemi-
cal progression” patients can evolve to “follow-up
after biochemical progression,” “metastasis,” or
“death.” Finally, patients in the state “metastasis”
may stay in “metastasis” or evolve to the state
“death.” Before death, all patients move through
the hormone refractory state.
 
Cost  of  adjuvant  treatment. 
 
The annual cost of
bicalutamide, at a daily dose of 150 mg, is 4891
 
€
 
(Ofﬁcial Belgian Reimbursement Tariff, 2002). The
current clinical data on bicalutamide are based on
median treatment duration of 2 years; however, the
most effective treatment duration is to be deter-
mined. The three trials constituting the EPC
program  are  evaluating  the  long-term  outcome
of Casodex 
 
+
 
 standard care compared with
placebo 
 
+
 
 standard care. One trial has a planned
treatment duration of 2 years, another a duration
up to progression with a maximum of 5 years, and
the third trial is investigating treatment up to dis-
ease progression without deﬁning a maximum.
Therefore it is likely that, based on further data
becoming available, recommended treatment dura-
tion will increase. To take a conservative approach,
avoiding underestimation of bicalutamide treat-
ment cost, a 5-year duration of bicalutamide is
assumed in the current analysis.
 
Table 1
 
Sensitivity analyses
 
Base case analysis
Parameter tested Base case value Tested values
Cost-effectiveness
27,059
 
€
 
QALY
Cost-effectiveness (Cost/QALY)
Time horizon (y) 15 10 71,980
20 16,066
Mortality objective progression Casodex 0.235 0.400* 32,688
Cost PSA progression (
 
€
 
) 0 5000 14,723
Annual discounting life years 3% 0% 20,157
Casodex treatment duration (y) 5 3 14,359
Daily cost of  gynecomastia
 
†
 
 (
 
€
 
) 0 0.736 28,772
Utility during Casodex treatment 0.9320 0.9000 54,832
Utility score PSA progression 0.9000 0.850 24,088
0.9395
 
‡
 
29,981
 
*Median survival of  16 month, this is lower than current reports in hormone refractory prostate cancer.
 
†
 
Daily treatment cost 
 
=
 
 cost of  Tamoxifen 20 mg (
 
€
 
0.736/day ofﬁcial tariff, 2003). This cost is applied to all patients with gynecomastia or breast pain who continue
treatment and it is additional to the 20% preventive radiotherapy from the base case.
 
‡ 
 
=
 
 utility score 
 
=
 
 follow-up without complications 
 
=
 
 best possible health state after EPC.
 
Figure 1
 
Simpliﬁed structure of  the health economic model.
Biochemical progression 
+ follow-up 
Early prostate cancer  
+ follow-up 
Death Hormone  
refractory 
Metastasis  
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After an average of 6 months, based on clinical
trial observations, 25.8% of patients stop bicaluta-
mide treatment for reasons not related to disease
progression (e.g., adverse events). The bicalutamide
cost calculations take into account these interrup-
tions, by attributing to 25.8% of patients only
6 months costs. Because the clinical data applied in
the model are intention-to-treat data, the interrup-
tion of bicalutamide in 25.8% of patients is
accounted for implicitly in the clinical outcomes.
Hence, no adaptation of transition probabilities is
required. Adverse events likely to be signiﬁcant
from an economic point of view (e.g., excluding hot
ﬂushes with probably limited economic impact) and
reported to differ signiﬁcantly between the study
populations include gynecomastia and breast pain
(Table 2). Mild to moderate gynecomastia or breast
pain (90% of reported cases) are assumed in the
base-case not to induce important health-care costs,
because these adverse events have been accepted by
patients and physicians as tolerable side effects of
treatment for advanced prostate cancer [9]. Reports
on current practice, however, show that patients are
increasingly being offered preventive radiotherapy
of the breast [9,10]. This is currently a possible
approach in prostate cancer patients for whom
restoring estrogen–androgen balance via hormone
therapy is inappropriate [10]. In our analysis, a
maximum of 20% of bicalutamide patients are
assumed to receive the offered preventive radiother-
apy option [9], at a unit cost of 541.81
 
€
 
 (Ofﬁcial
Belgian Reimbursement Tariff, 2002). Severe cases
(10% of reported cases) of gynecomastia or breast
pain are considered to require intervention.
Because, however, 15.7% of trial patients stopped
treatment for this event, moderate to severe cases
are assumed to discontinue treatment. Treatment
cessation due to disease progression on the other
hand is taken into account in the model by switch-
ing to a health state related to disease progression.
Because some promising data have been reported in
prostate cancer patients on the treatment of gyne-
comastia with tamoxifen, in sensitivity analysis,
patients with mild to moderate gynecomastia or
breast pain were considered to receive daily
tamoxifen throughout bicalutamide treatment
(Table 1).
 
Cost  of  follow-up. 
 
Routine follow-up in primary
prostate cancer patients from a US center was trans-
lated into costs for the current analysis as shown in
Table 3 [11]. Dutch guidelines reported similar fol-
low-up schedules [12].
 
Cost of biochemical progression. 
 
There was a sig-
niﬁcant difference between treatments in the rate of
PSA progression. Nevertheless, no costs are attrib-
uted to PSA progression in the base-case evaluation
because current management of PSA progression in
Belgium is unknown. Furthermore, personal inter-
views with Belgian physicians revealed that cur-
rently the medical management in the case of PSA
progression is variable among centers, both in terms
 
Table 2
 
Incidence rates of  gynecomastia and breast pain (EPC program)
 
Casodex Placebo
% incidence % withdrawal % incidence % withdrawal
Gynecomastia 13.1 3.5 4.8 0.2
Breast pain 19.7 5.8 4.3 0.2
Gynecomastia 
 
+
 
 breast pain 53.1 6.4 2.9 0.1
All 85.9 15.7 12.0 0.5
 
Source: data on ﬁle, AstraZeneca.
 
Table 3
 
Cost calculations for follow-up in EPC [9]
 
Unit cost (
 
€
 
)
DRE
0
PSA
2.31
Visit urol/oncol
9.90
Laboratory honorary
22.95 Total cost/year
Year one
 
n
 
4 4 4 4
Cost 0 9.24 39.60 91.80 140.64
Year two
 
n
 
2 2 2 2
Cost 0 4.62 19.80 45.90 70.32
Subsequent years
 
n
 
1 1 1 1
Cost 0 2.31 9.90 22.95 35.16
 
DRE, Digital rectal examination; urol, urologist; oncol, oncologist.
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of the timing of action (level of PSA rise) and in
terms of actions taken (medical intervention vs.
increased intensity of follow-up). Yet, PSA progres-
sion has been considered in the model structure
given that PSA doubling time has signiﬁcant power
to predict further disease progression [13], and clin-
ical guidelines, although without consensus on the
threshold, advise medical action, or alteration of
treatment or follow-up, in case of rising PSA
[12,14].
 
Cost of metastatic prostate cancer. 
 
Resource utili-
zation associated with metastatic prostate cancer
was based on a retrospective patient chart analysis.
Five centers participated in the study, and a total of
60 patient charts were reviewed. In each center, a
random selection was made from all patients con-
sulting for metastatic prostate cancer during the
course of 2000 or 2001. Patients were included if
followed in the respective center from study entry
for  at  least  1 year  or  up  to  death.  Participation
in  a clinical trial was an exclusion criterion. All
resources directly or indirectly related to metastatic
prostate cancer, were recorded during the 1-year
study period. The analyzed items included diagnos-
tic and follow-up tests, drugs, physician consults,
both ambulatory and in-hospital visits, and inter-
ventions. Costs for each item were calculated by
multiplying the unit cost with the number of units
consumed. Unit costs for interventions, investiga-
tions, and medical visits were derived from the ofﬁ-
cial listings of the Belgian Health Insurance INAMI/
RIZIV (2002). Unit costs for medication were based
on the ofﬁcial listings of the Belgian center for phar-
macotherapeutic information (2002). The unit cost
for hospitalization was derived from hospital
invoices from the involved oncology centers. The
method of patient selection ensures inclusion of
patients at different stages of metastatic prostate
cancer: recently diagnosed, follow-up of stable dis-
ease, progression, or ﬁnal progressive stage before
death. This is illustrated by the patient characteris-
tics such as age distribution, time since diagnosis,
and mortality rate (Table 4). Subgroup analyses
with regard to treatment options (chemotherapy vs.
no chemotherapy) or disease stages (metastasis at
initial diagnosis vs. metastasized initially EPC)
revealed no relevant differences in management
costs. Although the cost study was not designed to
show cost differences among treatment groups, the
result suggests that the average cost obtained from
the chart review is representative for the health state
“metastatic prostate cancer” throughout the model.
An average total annual cost for the management of
metastatic prostate cancer of 10,238€ was obtained.
Table 5 shows the cost division into predeﬁned cat-
egories.
Transition between health states.
 
 
 
Annual rates of
disease progression were calculated from published
 
Table 4
 
Patient characteristics
 
Patient characteristics Mean SD Range % of  patients
Age at study entry (years) 72.1 9.2 53–93
Years since initial diagnosis 5.8 3.6 1–16
Years since metastasis diagnosis 3.7 2.3 1–9
Patient characteristics
Metastasis present at initial diagnosis (%) 36.7
Early prostate cancer at initial diagnosis (%) 35.0
TNM stage unknown at initial diagnosis (%) 28.3
Conﬁrmed metastasis bone (%) 71.7
Conﬁrmed metastasis other (%) 28.3
One site metastasis (%) 26.7
Metastasis site unknown (%) 15.6
Death during 1 year follow-up (%) 21.7
Patient management
Hormone therapy
Biphosphonates (%) 37.0
Zoladex (%) 47.0
Casodex (%) 28.0
Eulexin (%) 15.0
Chemotherapy (%) 53.0
Radiotherapy 28.3
Surgery 23.3
Treatment before study entry
Surgery 48.9
Radiation therapy 40.0
Hormonal therapy 71.1
Chemotherapy 20.0
Unknown 8.9
 
Source: chart review by HEDM.
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risks applying the following formula for transfor-
mation of observed risks into annual rates [8]:
Rate (1 year) 
 
=
 
 1 
 
-
 
 (1 
 
-
 
 Risk
 
x year
 
)
 
1/
 
x
 
Transitions from early prostate cancer to
subsequent states. 
 
The rate of direct progression
from EPC to biochemical, objective progression or
death and the rate of objective metastasis after PSA
progression are available from the ﬁrst combined
analysis of the bicalutamide EPC program at a
median follow-up of 3 years [3]. The observed
number of patients with PSA doubling, with meta-
static progression, with metastasis after PSA dou-
bling, and the number of deaths are reported in
Table 6. The table also includes the calculated
annual risks with their 95% conﬁdence intervals.
These annual transition rates were applied through-
out the model. Nevertheless, in both strategic arms,
a same time factor was built in to simulate the slow-
ing of annual progression rates with time since diag-
nosis (see further). Mortality data were immature
for analysis and most patients died from non-
prostate-cancer-related causes. Therefore, the direct
model transition from EPC as well as from PSA pro-
gression to death was considered equal in both
groups (Table 6). Because this all-cause mortality is
related to age, it was gradually increased through-
out the model based on the triennial relative
increase in the age- and sex-adjusted all-cause mor-
tality, published by the Belgian National Institute
for Statistics (NIS).
 
Transition probability from objective progression to
death. 
 
Meta-analysis from 27 randomized trials,
involving 98% of the worldwide randomized evi-
dence revealed a 5-years mortality rate of 73.8%
with MAB (maximal androgen blockade) com-
pared to 75.9% with androgen suppression alone
in patients with objective metastasis (excluding
the cases with locally advanced disease (12%))
[15]. The calculated annual death rate of 0.2350
for MAB treatment is applied in the base-case
model.
 
Modeling  progression  as  a  function  of  time.  
 
It
could be argued that the PSA progression risk
decreases with time. Pound et al. [11] demonstrated
approximately 50% lower annual rates at 9 years
after diagnosis compared with the ﬁrst 2 years after
diagnosis. Therefore, a 50% decrease has been built
into the model as from year 5 only. It could also be
argued that the predictive value of PSA doubling for
subsequent objective disease progression is time-
dependent. Indeed, Roberts et al. [13] reported an
annual rate of progression of 0.1599 in the case of
a PSA doubling time of less than 1 year after diag-
nosis compared to a rate of 0.0912 (
 
=
 
 57% of
 
Table 5
 
Cost of  metastatic prostate cancer
 
Resource use Average cost (
 
€
 
) SE
Imaging techniques  370 51
Laboratory tests 
 
+
 
 other tests  193 18
Hormonal therapy 2,788 397
Chemotherapy  837 292
Surgery  108 42
Radiation therapy  378 77
Medication  329 74
Hospitalization 4,966 973
Consults  174 22
Interventions  95 31
Total 10,238 1178
 
Source: chart review by HEDM.
 
Table 6
 
Clinical data applied in the model
 
Casodex PSA doubling Objective progression Objective after PSA
 
†
 
Death ﬁrst event
Sample size 4052 4052 385 8113
 
n
 
 events 385 102 65 354
Proportion (%) 9.501 2.517 16.883 4.363
95% CI* 8.598–10.40 2.035–3.000 13.136–20.630 3.919–4.808
Risk/year 0.0327 0.0085 0.1160 0.0148
 
‡
 
95% CI 0.0295–0.0359 0.0068–0.0101 0.0896–0.1428 0.0132–0.0163
Control
Sample size 4061 4061 1016 8113
n events 1016 145 223 354
Proportion (%) 25.018 3.571 21.949 4.363
95% CI* 23.686–26.351 3.000–4.141 19.402–24.495 3.919–4.808
Risk/year 0.0915 0.0120 0.1523 0.0148
 
‡
 
95% CI 0.0862–0.0969 0.0101–0.0140 0.1339–0.1708 0.0132–0.0163
 
*Assuming a binomial distribution.
 
†
 
Based on an assumed median follow-up duration of  1.5 years after PSA progression.
 
‡
 
The number represents the initial transition probability. Subsequently, the mortality rate is adjusted to the age- and sex-matched relative increase in mortality with age,
published by the National Institute for Statistics (1997).
Source: data on ﬁle, AstraZeneca.
CI, conﬁdence interval.
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0.1599) in the case of a PSA doubling time of
between 1 and 9.9 years. In view of these ﬁndings,
the rate of progression after PSA rise was pro-
grammed in the model as follows. The “post-PSA
progression rates” observed in the EPC program
were applied over the initial 3 years (
 
=
 
 median fol-
low-up in the EPC program). Subsequently, beyond
the observed time range, 57% of the baseline
annual rate was applied. A third factor requiring
adaptation as a function of time is the annual all-
cause mortality because this is affected by age. Dur-
ing the ﬁrst 3 years the annual rate from the EPC
program was applied in the model. Subsequently
every 3 years a correction was applied based on age-
adapted male mortality rates reported by the Bel-
gian National Institute for Statistics (NIS, 1997).
 
Utilities. 
 
Quality of life (QOL) was taken into
account by attributing to each health state in the
model a utility value from 0 to 1 where 0 represents
death and 1 represents perfect health. The utility
values were obtained from published literature (see
below). During each cycle the model calculates the
weighted average utility value based on the propor-
tional distribution of patients over different health
states. By running the model, the cumulative mean
utility values for both strategic arms are calculated,
representing the mean total number of QALYs accu-
mulated over the time horizon analysed.
Several authors have reported utility values
attributable to different stages of prostate cancer
[16–19]. For EPC we applied data from Smith et al.
[16], which were obtained with two standard meth-
ods (standard gamble and time trade off) from a
large sample of patients having undergone radical
prostatectomy, the most frequently applied treat-
ment for EPC. Based on the reported utility scores
for patients with or without complaints of urinary
incontinence or impotence [16], and the respective
incidence rates reported in the EPC program (6%
urinary incontinence in both groups and 9% vs.
6.1% impotence in the bicalutamide and placebo
group, respectively [3]) a weighted average utility
score of 0.9320 was calculated for bicalutamide
patients and of 0.9337 for placebo patients. Gyne-
comastia and hot ﬂushes have been reported not to
have a signiﬁcant impact on utilities [18], and the
impact of breast pain has not been evaluated.
Therefore, the latter events were not included in the
utility calculations. Because the actual impact of
these events on utility values is uncertain, the utility
value during bicalutamide treatment was assumed
to be only 0.9 in sensitivity analysis (Table 1). With
regard to biochemical progression unfortunately no
utility scores have been reported. Nevertheless, Wei
et al. [20] showed in a cross-sectional survey that
progression-free patients report marginally better
health-related QOL (HRQOL) than those with PSA
elevation. Mean scores for sexual HRQOL were
37.1 vs. 26.7 in progression-free vs. PSA-progres-
sion subjects; hormonal HRQOL scores were 90.3
vs. 84.7, respectively (both signiﬁcant differences
 
P
 
 
 
<
 
 0.0001). The latter may be caused by secondary
treatment. Lower utilities may also be caused by the
impact of the patient’s knowledge that a PSA eleva-
tion has been detected. Nevertheless, in their survey,
Wei et al. [20] did not speciﬁcally address the poten-
tial detrimental effect of the patient’s knowledge of
PSA elevation on QOL. Therefore, in the base-case
analysis, a utility score of 0.9 was assumed in the
“PSA progression” health state. A sensitivity anal-
ysis was performed to assess the impact of this
assumption (see below). For metastatic patients,
Rosendahl et al. [18] reported utilities relative to
the best possible health state in case of prostate can-
cer. Considering EPC follow-up without symptoms
or progression as the best possible health state
(utility 
 
=
 
 0.9395), the results from Rosendahl [18]
translate to 0.855 for stable metastatic disease with-
out toxicity, 0.799 for progression and 0.714 for
progression with pain (applied as representative for
late progression). In the model, before death
patients are assumed to be in late progression for
their last Markov cycle.
To take into account the uncertainty around clin-
ical and economic parameters used in the model and
to estimate a conﬁdence interval around the incre-
mental cost-effectiveness ratio, a probabilistic sen-
sitivity analysis was performed using the Monte-
Carlo simulation method [21]. Because the clinical
parameters used in the model resulted from a clin-
ical trial, the uncertainty of these clinical parame-
ters is given by the variance, based on which a
normal distribution was simulated. A thousand sets
of input parameters were randomly sampled.
 
Results
 
Base Case
 
On average, 89% of men with prostate cancer have
been estimated to live at least 5 years, and 63% at
least 10 years [15]. Mortality curves obtained by
running the model over 15 years are shown in
Fig. 2.
The survival rates predicted by the model (Fig. 2,
Table 7) support the validity of the model in terms
of predicting the natural history of EPC. The cost
analysis (Table 7) shows that the total cost in the
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bicalutamide arm is higher than the total cost in the
standard care group. The cost of metastasis, how-
ever, is higher in the standard care group, reﬂecting
the higher rate of disease progression in the absence
of adjuvant hormone therapy. PSA progression and
metastatic progression curves for the “bicaluta-
mide” and “no bicalutamide” arms, obtained by
Markov analysis, diverge during the initial years
and slowly converge thereafter (Fig. 2). Note that,
at each point in time, the curves (Fig. 2) are mutu-
ally exclusive. For example, a deceased patient who
died after metastatic relapse is represented in the
mortality curve. Figure 3 shows the disease-free sur-
vival predicted by the model over 15 years. The
health impact (QALY) analysis is presented in
Table 8. For both study arms, an overview is pro-
vided of the time spent in each stage of disease pro-
gression (EPC, biochemical progression, metastasis,
death), the utility value attributed to one cycle in the
respective disease stage and the resulting cumulative
number of QALYs over a 15-year time horizon.
At a time horizon of 15 years, the incremental
cost-effectiveness of Bicalutamide equals 27,059
 
€
 
/
QALY (Table 7). This seems to be an acceptable
result, in comparison to other interventions in can-
cer (see for instance [22]).
 
Sensitivity Analyses
 
The results of sensitivity analyses performed to test
the robustness of conclusions are shown in Table 1.
The time horizon appears to be a very important
factor inﬂuencing the outcome of the model. Anal-
yses performed at a time horizon of 15 years or
more show bicalutamide to be cost-effective in the
management of EPC. A shorter time horizon, how-
ever, provides less favorable results from a health
economic point of view.
Adding a daily treatment cost for treatment of
adverse events, gynecomastia, and breast pain, does
not alter conclusions.
One of the model assumptions is that progno-
sis of metastatic prostate cancer in patients hav-
ing received adjuvant hormone therapy is
comparable to prognosis in controls. Neverthe-
less, it might be that prognosis is different because
of an increased risk of hormone-independent can-
cer. Although evidence to support this hypothesis
is lacking, sensitivity analysis was performed to
assess its possible inﬂuence on conclusions. Cost-
effectiveness of bicalutamide is moderately
sensitive to this parameter: assuming metastatic
mortality rates above the currently reported
mortality rate in hormone refractory patients [23]
 
Figure 2
 
Progression and mortality curves
produced by running the model (Markov
analysis).
0
0.1
0.2
0.3
0.4
0.5
0.6
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Years
Pr
ob
ab
ilit
y
No Casodex death
Casodex death
No Casodex PSA
progression
Casodex PSA
progression
No Casodex metastasis
Casodex metastasis
 
Table 7
 
Predicted outcomes of  the model
 
Predicted outcome Casodex (% of  pts) Placebo (% of  pts)
5 years overall survival  89 87
10 years overall survival  72 66
15 years overall survival  52 43
20 years overall survival  32 24
Cost analysis 15 years Casodex (
 
€
 
) Placebo (
 
€
 
)
EPC costs 17,439.7 451.6
Metastasis costs 4,616.0 9038.7
Total costs 22,055.7 9490.3
Incremental cost 12,565.4
Cost-effectiveness 15 years
# QALY  9.412 8.948
Incremental QALY  0.464
Incremental Cost/QALYG (
 
€
 
) 27,059
 
EPC, early prostate cancer; Pts, patients.
 Bicalutamide in Early Prostate Cancer
 
479
 
increases incremental cost-effectiveness to 32,688
 
€
 
per QALY.
The additional cost of PSA progression has been
conservatively set at zero in the model. It is clear,
however, that at least a proportion of these patients
will incur supplementary costs due to treatment and
follow-up. To conﬁrm that including a cost for PSA
progression would improve the cost-effectiveness of
bicalutamide, an arbitrarily chosen annual cost was
implemented from PSA doubling until further dis-
ease progression. At an annual cost of 5000
 
€
 
 for
PSA progression, the incremental cost-effectiveness
of bicalutamide would only be 14,723
 
€
 
 per QALY.
Not discounting QALYs improves the incremental
cost-effectiveness signiﬁcantly. This is due to the
slow progression of the disease implying that a large
proportion of the QALYs gained take place after
many years and are therefore discounted at a high
rate. The duration of bicalutamide treatment inﬂu-
ences the cost-effectiveness results (Table 1). In the
base-case a “maximal” estimate of 5 years duration
was applied in the cost calculations. Shorter dura-
tions (
 
=
 
 lower cost) are associated with lower cost-
effectiveness ratios. The current model was based
on progression rates from the clinical trial program
with a median treatment duration of 2 years and a
median follow-up duration of 3 years. The model
assumes that 5-year treatment will ensure long-term
maintenance of the observed beneﬁts: direct pro-
gression rates observed in the clinical trial program
in both study arms are maintained throughout the
model, albeit that in both arms the same relative
decrease in disease progression over time was pro-
grammed as explained earlier. The recommended
duration of dosing may change with further follow-
up and the actual clinical advantage of 5 years dura-
tion as opposed to 2 years will be shown when
further data become available.
Finally, a sensitivity analysis was performed test-
ing the impact of bicalutamide efﬁcacy.
Including  the  key  clinical  input  variables  in
a Monte Carlo evaluation provides a cost-
effectiveness acceptability curve as shown in
 
Table 8
 
Utility value per disease stage, time spent in each disease stage, cumulative N QALYs—Casodex vs. no Casodex
 
Casodex No Casodex
Utility value Time (years) Utility value Time (years)
EPC 0.9320 10.2 0.9337 7.7
PSA progression 0.9 1.4 0.9 2.8
Metastasis* 0.714–0.855 0.6 0.714–0.855 1.1
Death 0 2.8 0 3.4
Cumulative 9.412 15 8.948 15
 
*Different utilities for stable disease, early, and late progression.
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Cost-effectiveness acceptability curve.
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Figure 4. If societal willingness-to-pay for a QALY
obtained with bicalutamide is 35,000
 
€
 
/QALY, then
the probability of the drug being considered “value
for money” is 80%. If the threshold becomes
35,000
 
€
 
, then this probability becomes almost 95%.
 
Discussion
 
We performed a cost-effectiveness analysis of bical-
utamide in adjuvant treatment of prostate cancer,
based on disease progression data from the clinical
development program and local cost data. Bicaluta-
mide was found to be cost-effective in this clinical
setting (27,059
 
€
 
/QALY). The conclusion is robust,
provided that a sufﬁcient time horizon of at least
15 years is taken. This impact of time horizon on
cost-effectiveness of early cancer treatments has
been reported by others [24] and is inherently asso-
ciated with the typical situation of early stage can-
cer. Reasons include the different evolution of costs
with time in patients receiving adjuvant therapy vs.
controls [24]. Indeed, during the ﬁrst 5 years there
is an annual incremental cost related to the hormo-
nal treatment. In subsequent years, only the clinical
beneﬁt of past adjuvant treatment plays a role in
cost differences. Another reason is the relatively
slow progression in prostate cancer. If the analysis is
restricted to too short a time horizon, many of the
potential life years gained have not been reached.
Therefore, a minimal time horizon for the evalua-
tion of cost-effectiveness in early prostate cancer of
15 years should be applied [5].
In our analysis, data from a median follow-up
duration of 3 years were extrapolated with the aid
of modeling to a time horizon of 15 years. Given
the typical slow progression of the disease, it is
inevitable that we must use models to extrapolate
beyond the clinical data time horizon as well as
beyond the “intermediate outcomes” of clinical tri-
als [25]. The model, however, was shown to be a
good predictor of mortality over 15 years. Further-
more, to account for the possible uncertainties
associated with the beneﬁts of the intervention in
the years beyond current data availability, we have
made conservative choices, that is, to the disadvan-
tage of bicalutamide’s cost-effectiveness throughout
the model. Another comment is that prognosis
after objective disease progression was assumed
equal in both study arms. It could be argued that
prognosis in patients developing metastatic pro-
gression after initial adjuvant therapy may be dif-
ferent. Most studies related to adjuvant therapy
have been relatively small but have reported an
advantage in overall survival (Chay, 2001 and
Messing, 1999 in [15]). Other trials looking at sur-
vival outcome after adjuvant hormone treatment
are ongoing [15]. Hormone-refractory trials on the
other hand have included very heterogeneous pop-
ulations for example with regard to time since
metastasis [26]. In view of these ﬁndings, it is
deemed justiﬁed to apply the same survival rates to
patients developing metastasis in both treatment
arms. As long-term data from the clinical trial pro-
gram become available, the validity of the model
can be tested further, and if necessary, adaptations
can be performed. No attempt was made to per-
form subgroup analysis. Nevertheless, in practice
bicalutamide may not be cost-effective in all
patient groups: different patients may have differ-
ent risks of progression (related to, e.g., the
Gleason score, a histological grading score for
tumor cell differentiation) and different life expect-
ancy (related to, e.g., age or comorbidities) as a
result of which they would be more or less likely to
beneﬁt from adjuvant hormone treatment. In real
life, many factors play a role in the physician’s and
patient’s choice of treatment, among which are age,
comorbidities, life expectancy, and tumor charac-
teristics (TNM stage, Gleason score). It is therefore
likely that in real life, those patients most likely to
beneﬁt from adjuvant treatment will be selected for
it. In conclusion, our data suggest bicalutamide
adjuvant treatment in EPC to be a cost-effective
intervention when compared to other well-
established interventions in health care.
The study was funded by an unrestricted research grant
from AstraZeneca, Brussels, Belgium.
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